What Is the Future of CTLA-4 Inhibitors in Cancer Therapy?
The future of CTLA-4 inhibitors in cancer therapy looks promising, with ongoing research aimed at improving their efficacy and safety. Combination therapies that include CTLA-4 inhibitors and other immune checkpoint inhibitors, such as PD-1 or PD-L1 inhibitors, are showing encouraging results. These combinations can potentially enhance antitumor activity and overcome resistance mechanisms. Additionally, the development of novel biomarkers may allow for more personalized treatment approaches.
